about
Idiopathic Pulmonary Fibrosis: Treatment and PrognosisEfficacy and safety of nintedanib in idiopathic pulmonary fibrosisDouble-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia - short term evaluation of safety and tolerability.An autopsy study of combined pulmonary fibrosis and emphysema: correlations among clinical, radiological, and pathological features.COPD advances in left ventricular diastolic dysfunction.A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE SPirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis.Pulmonary mucosa-associated lymphoid tissue lymphoma associated with pulmonary sarcoidosis: a case report and literature review.Cyclic mechanical stretch-induced oxidative stress occurs via a NOX-dependent mechanism in type II alveolar epithelial cells.Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.Subgroup analysis of Asian patients in the INPULSIS(®) trials of nintedanib in idiopathic pulmonary fibrosis.Nrf2 Regulates the Risk of a Diesel Exhaust Inhalation-Induced Immune Response during Bleomycin Lung Injury and Fibrosis in Mice.Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis.Sub-speciation of Mycobacterium tuberculosis complex from tuberculosis patients in Japan.Prognostic Factors in the Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Single-center Study.Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema.Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation.Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation.An on-site preparable, novel bone-grafting complex consisting of human platelet-rich fibrin and porous particles made of a recombinant collagen-like proteinLong-term safety of pirfenidone: results of the prospective, observational PASSPORT studyNintedanib for Systemic Sclerosis–Associated Interstitial Lung DiseaseA Community-Level Initiative to Prevent Obesity: Results From Kaiser Permanente's Healthy Eating Active Living Zones Initiative in CaliforniaPrognostic significance of ventricular late potentials in patients with pulmonary sarcoidosisSafety management of treatment with nintedanib in clinical practice of IPFJapanese guideline for the treatment of idiopathic pulmonary fibrosisReply to: Too Premature to Deny the Potential of Thrombomodulin-alfa in Idiopathic Pulmonary FibrosisDiffuse panbronchiolitis: A fine road from the discovery of a disease to the establishment of treatmentJCS 2016 Guideline on Diagnosis and Treatment of Cardiac Sarcoidosis - Digest VersionTherapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trialsLung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosisPrimary ciliary dyskinesia caused by a large homozygous deletion including exons 1-4 of DRC1 in Japanese patients with recurrent sinopulmonary infection[The Latest Information on Respiratory Disease Management. Topics: III. New Treatment of Idiopathic Pulmonary Fibrosis]Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice GuidelineNintedanib: New indication for systemic sclerosis-associated interstitial lung diseaseExosome-derived microRNA-22 ameliorates pulmonary fibrosis by regulating fibroblast-to-myofibroblast differentiation both in vitro and in vivoActivated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic StrategiesSevere Pneumonitis with Alveolar Hemorrhage Associated with Herbal Medicines: A Case ReportAnalysis of the Genetic Diversity and Structure of the Grey-Faced Buzzard (Butastur indicus) in Japan, Based on mtDNAWeekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study
P50
Q28073641-05D6EBB7-3BED-4B61-8749-F412E5450566Q28240230-E704083A-3310-44E5-8D27-D122D6B0D3A9Q33657810-073E3580-1231-405D-88D1-0E26DA9C7E54Q33907271-B0B1B5FE-AFEB-4679-B70F-7DA33A84DAD5Q36763609-D8AF4A4C-4F78-420A-99AE-5D70AC75573CQ37118198-C2C99207-5542-4893-B73D-142A80A602D5Q37594827-09F61911-17DE-4B44-97E9-A0B305CE4FF4Q38805291-51961206-CA8B-4C37-B1A9-4983861B68D8Q38820180-BC5C21C8-C7C1-45E8-8158-028A36DDCE1AQ39084182-2EC63248-0491-42AC-A022-442116F0E071Q39614995-E7D04234-4D64-4D00-A62A-CD2B57253426Q40290145-1FC7CAC4-462C-48EC-9029-C804F921258EQ40875887-4743CB9D-FA51-4CFC-BB24-3CDA9AA53E1DQ46976265-0AD5A266-3D0B-45FC-8AD6-F361B443B1DCQ47450001-E7D95949-7F6C-406E-849D-55E713B3A9E4Q47659355-AC55D75F-92C3-4768-8E77-D0DEA463AAE9Q50673968-1A1115DF-5FAC-44C8-9B11-3E60D2B3E6BEQ51359224-1215A6C4-187F-4537-A693-C2BEAE84D209Q55271396-0B3892CA-67DA-4254-8C42-D5735FE7A7C9Q57056893-243526E8-0482-4B67-8828-25F98D9F42E2Q58587295-17E1D205-B420-46DF-A588-70DD6D2E4C2CQ64005207-6C711C0A-D52D-4D3B-A401-011707AB9704Q88429838-5806BAF3-EA54-488E-9331-1A5DBF51E9C8Q88953524-DC061E55-1A6E-4018-B8BA-84333A98AE14Q89223083-B7D96BC1-E608-4953-ACA1-61AD14B86AD8Q89448424-11C86F1C-C629-40C4-8E47-9819F923B6BAQ90159372-60F32555-4B91-4A6B-A8A0-91EBE21FE8AAQ90516612-31ACFDA4-1FD4-46EC-A59C-4CA3362B54F8Q90617009-6616C453-0A77-4E7C-BDC1-A1DFF2D1C3A5Q91098395-E10CF470-1DE3-475A-9A89-21AC2150A734Q91146281-3EB04AA0-643D-45AD-B541-6D5F1F4FCBBCQ91182284-B2931B61-2D1A-41E1-8407-2B1E02B2C8E9Q91246999-38E2CB27-09A3-4371-8095-A2DD1DA4E5B6Q91247291-3FAF5C6B-57DA-47DE-9478-BC6B83C73563Q91358600-D18E9DC0-EA38-4521-A8D2-2E59227A12FCQ91496359-130C9298-7D49-4C47-A19B-5C690C26B25BQ91857825-70D5D5A8-C93E-416C-92AD-D95A6F80A48BQ92144273-212B97DB-8750-4589-8389-28620A8180FBQ92214980-2F4B2AA5-3184-407C-98F1-C60AAB3E5ECAQ92227266-BF54BC72-3BDD-4355-9652-714B7B33B51B
P50
description
researcher
@en
name
Arata Azuma
@en
type
label
Arata Azuma
@en
prefLabel
Arata Azuma
@en
P31
P496
0000-0003-0506-9966